Categories: NewsPatient Care

Tomoverse Imaging Inc. Announces Closing of $5 Million Dollar Seed Funding Round Led by Strategic Canadian Family Office

MONTRÉAL, July 11, 2025 /PRNewswire/ – Tomoverse Imaging Inc., a medical software company pioneering advanced CT imaging solutions for structural heart interventions, today announced the successful closing of its $5M Seed funding round, led by a prominent Canadian Family Office.

This funding milestone marks a significant advancement for Tomoverse, developer of tvCT, a flagship platform designed to modernize and streamline planning and execution of complex transcatheter cardiac procedures. Built by physicians for physicians, tvCT provides intuitive, high-performance tools that enable clinicians to enhance patient care and optimize procedural outcomes. The platform integrates advanced AI-based automated capabilities, significantly improving accuracy and efficiency in clinical workflows.

The capital raised will be directed toward completing software development, advancing clinical studies, and securing regulatory clearances from the U.S. Food and Drug Administration (FDA), Health Canada, and other global regulatory bodies. Additionally, the funding supports Tomoverse’s strategic commercialization efforts in North America and key international markets.

“We are deeply grateful for the trust and confidence placed in us by our investors,” said Stuart Kozlick, CEO of Tomoverse Imaging Inc. “This strategic investment accelerates our product roadmap, enabling us to bring our innovative technology closer to patients and clinicians who need it most.”

Tomoverse aims to become the global standard in CT imaging solutions for structural heart interventions — a rapidly growing sector transforming patient care and procedural efficiency worldwide.

About Tomoverse Imaging Inc.

Tomoverse Imaging Inc. (www.tomoverse.tech) is a Montreal-based medical software company specializing in advanced cardiac CT imaging solutions for structural heart and coronary interventions. Its flagship platform, tvCT, delivers intuitive, cloud-based tools that enhance procedural planning, improve clinical outcomes, and support education and research in interventional cardiology. Founded by leaders in cardiology, computational imaging, and medtech innovation, Tomoverse is dedicated to transforming how clinicians plan and execute complex heart procedures worldwide.

Caution: the tvCT software platform is not approved and not for sale in any geography.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tomoverse-imaging-inc-announces-closing-of-5-million-dollar-seed-funding-round-led-by-strategic-canadian-family-office-302503031.html

SOURCE Tomoverse Imaging

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

3 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

3 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

3 hours ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

3 hours ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

3 hours ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

6 hours ago